Dr. Marshall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
Johns Hopkins UniversityFellowship, Medical Oncology, 2017- Johns Hopkins UniversityResidency, Internal Medicine, 2012 - 2015
- Johns Hopkins University School of MedicineClass of 2012
Certifications & Licensure
MD State Medical License 2015 - 2026
PA State Medical License 2024 - 2026
VA State Medical License 2021 - 2026
NH State Medical License 2024 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial to Promote Recovery From COVID-19 With Endocrine Therapy Start of enrollment: 2021 Apr 01
- Camostat With Bicalutamide for COVID-19 Start of enrollment: 2021 Feb 03
Publications & Presentations
PubMed
- Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer.Etan R Aber, Michael A Carducci, Channing J Paller, Sam R Denmeade, Kelli Rourke
The Prostate. 2025-03-01 - Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly.Catherine H Marshall, Emmanuel S Antonarakis, Mrinal M Patnaik
Blood Reviews. 2025-03-01 - Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.Ali T Arafa, Siddhartha Yadav, Catherine H Marshall, Elizabeth Mauer, Minxuan Huang
Clinical Cancer Research. 2025-02-28
Lectures
- Cardiorespiratory fitness and incident lung and colon cancer: FIT-Cancer Cohort.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Prevalence of homologous recombination deficiency (HRD) mutations in localized prostate cancer according to Gleason grade: Implications for neoadjuvant clinical trial ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Olaparib Without ADT Benefits HRR-Mutated High-Risk Recurrent Prostate CancerAugust 30th, 2024- Olaparib Monotherapy Yields Good PSA Response Rates in Prostate CancerAugust 27th, 2024
- ASCO 2022 HighlightsJuly 27th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
